Fifth US Biosimilar To Herceptin Launched By Merck

Ontruzant Biosimilar Available For All Eligible Indications

Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.

Crowds
The biosimilar trastuzumab market in the US is becoming increasingly crowded, with five players • Source: Shutterstock

The market for trastuzumab in the US is becoming increasingly crowded with Merck & Co. today launching Samsung Bioepis’ Ontruzant (trastuzumab-dttb) in two strengths, representing the fifth biosimilar to Genentech’s Herceptin available in the country, at a discount competitive with those offered by several other biosimilar players.

Merck’s approval and launch of the biosimilar, which marks Samsung Bioepis’ first oncology biosimilar in the US, spans all eligible...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.